Muhannad Al-Kilani, MD
Endocrinology, Diabetes & Metabolism · Sikeston, MONPI 1205857216
Payments from drug & device makers
Across 186 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$871
- Amgen$410
- Boehringer Ingelheim$394
- Sanofi-aventis U.S. LLC$306
- Lilly USA, LLC$268
- Radius Health, Inc.$258
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,67588%
- Education$52212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $871 |
| Amgen | 19 | $410 |
| Boehringer Ingelheim | 22 | $394 |
| Sanofi-aventis U.S. LLC | 17 | $306 |
| Lilly USA, LLC | 14 | $268 |
| Radius Health, Inc. | 13 | $258 |
| Bayer | 11 | $222 |
| Corcept Therapeutics | 9 | $200 |
| Abbott | 10 | $194 |
| Ascendis Pharma Endocrinology Inc | 4 | $180 |
| Insulet Corporation | 4 | $141 |
| Medtronic | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 6 | $121 |
| AstraZeneca | 3 | $91 |
| Amarin Pharma, Inc. | 1 | $77 |
| Merck | 4 | $62 |
| Dexcom, Inc. | 3 | $57 |
| Novartis | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Shire North American Group Inc | 1 | $25 |
| BETA Bionics, Inc. | 2 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Aegerion Pharmaceuticals, Inc. | 1 | $17 |
| Optos, Inc. | 1 | $16 |
| RGH Enterprises LLC | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $14 |
| Pfizer | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$125
- SKYTROFA$123
- Ozempic$102
How this compares
$4,197 in reported general payments places this provider in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 217 | $177,058 |
| TrulicityDulaglutide | 157 | $152,616 |
| MounjaroTirzepatide | 96 | $100,342 |
| Tresiba Flextouch U-100Insulin Degludec | 114 | $86,197 |
| OzempicSemaglutide | 79 | $74,879 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 86 | $66,309 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $60,376 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $58,256 |
| Humalog Kwikpen U-100Insulin Lispro | 226 | $48,032 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 74 | $34,643 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 255 | $32,356 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $30,387 |
| TradjentaLinagliptin | 38 | $29,892 |
| Novolog FlexpenInsulin Aspart | 131 | $27,398 |
| JanuviaSitagliptin Phosphate | 33 | $22,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30, Humalog Mix 75-25 | $268 | $262,877316 claims |
| Boehringer IngelheimJardiance, Tradjenta | $394 | $206,951255 claims |
| Novo NordiskOzempic, Novolog, Novolog Mix 70-30 | $871 | $80,925107 claims |
| MerckJanuvia | $62 | $22,74633 claims |
| AstraZenecaFarxiga | $91 | $20,89721 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $306 | $14,17913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Sikeston
- Ralph DudaSpringfield$3M
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Gregory LedgerSpringfield$690K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Julie SilversteinSaint Louis$536K
- Ralph OiknineChesterfield$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.